These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25354577)

  • 21. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study.
    Han X; Ma L; Zhao L; He X; Liu P; Zhou S; Yang J; Qin Y; Yang S; Yao J; Shi Y
    J Clin Apher; 2012; 27(2):64-74. PubMed ID: 22298390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
    Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
    Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience.
    Halacoglu A; Serefhanoglu S
    J Cancer Res Ther; 2024 Apr; 20(3):904-908. PubMed ID: 38102912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.
    D'Hondt L; Emmons RV; André M; Guillaume T; Feyens AM; Canon JL; Humblet Y; Longueville J; Symann M
    Leuk Lymphoma; 1999 Jun; 34(1-2):105-9. PubMed ID: 10350337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.
    Callera AF; Rosa ES; Callera F
    Transfus Apher Sci; 2019 Jun; 58(3):318-322. PubMed ID: 30961974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of two initial mobilizing strategies of peripheral blood stem cells for autologous transplantation in patients with lymphoma and human immunodeficiency virus infection].
    Sagüés M; Sancho JM; Serrano D; Balsalobre P; Gayoso J; Morgades M; Conde E; Iriondo A; Varela R; Escoda L; Xicoy B; Espigado I; Fernández-Abellán P; Díez JL; Ribera JM
    Med Clin (Barc); 2012 Jul; 139(5):192-6. PubMed ID: 21807388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
    Smardova L; Engert A; Haverkamp H; Raemakers J; Baars J; Pfistner B; Diehl V; Josting A
    Leuk Lymphoma; 2005 Jul; 46(7):1017-22. PubMed ID: 16019552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
    Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
    Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
    Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
    Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
    Kröger N; Zeller W; Fehse N; Hassan HT; Krüger W; Gutensohn K; Lölliger C; Zander AR
    Br J Haematol; 1998 Sep; 102(4):1101-6. PubMed ID: 9734664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.